Jeremie Calais, MD | Authors

Articles

Analyzing Responses to 177LuPSMA-617 in Patients With Metastatic CRPC

May 24, 2019

Jeremie Calais, MD, discusses the results from a preliminary analysis of a phase II trial investigating 177 lutetium prostate-specific membrane antigen-617 in patients with metastatic castration-resistant prostate cancer.